A Letter from Liz: Big Changes at T1International

A Letter from Liz: Big Changes at T1International

Facebook Google LinkedIn Twitter

As we begin 2024 and think about the plans for T1International this year and beyond, I wanted to share a personal update that is also a big organisational update.

After over a decade of leading T1International, the time has come for me to transition from my role as Executive Director by the end of 2024. This decision was not made lightly. I want to be clear that the decision has been guided by my firm belief that T1International should thrive independently, evolving with new perspectives and energy.

It has always been my hope that T1International will outlive my time with the organisation so that we can keep fighting until #insulin4all is truly achieved. Over the past three years, we've laid the groundwork for a smooth transition.

Our strategy for 2024 has three focus points and will solidify and grow our impact:

  • Programmatic Strength: We will continue to achieve major political campaign victories and celebrate at least 5 significant campaign wins to move us to our goal of #insulin4all.
  • Financial Resilience: We've begun to diversify our funding sources, moving away from reliance on a few funders. Our model will continue to embrace grassroots donors, major contributors, peer support, corporate giving, and grants.
  • Organisational Capacity: Building a formidable team has been a priority. We've aligned our work globally and regionally, and we will keep empowering our community to carry the torch of the #insulin4all mission forward by implementing a successful Executive Director transition.

I cannot tell you how proud and grateful I am to see how far we have come since the beginning, when T1International was nothing more than words on a website and a collection of stories that filled me with outrage and a strong drive to ensure independent patient voices were respected and amplified. Because of the outrage and hope of countless advocates worldwide, and the dedication and hours of blood, sweat and tears, we are a powerful voice for people with diabetes that has made real change. There will be a chance to begin to say farewell in September, at the T1International Toast, where we’ll be celebrating everything our community has achieved. Save the date and I hope to see you there!

I'm excited about the opportunities that await T1International under new leadership. This year we will be recruiting and onboarding a new Executive Director, with my support throughout the year to get them, and the team, ready for my departure. We're looking for a passionate and visionary leader to guide our organisation into its next chapter, building on the incredible foundation we've laid together.

If you or someone you know feels ready to take on this crucial role and be a driving force for #insulin4all, I encourage them to apply today! We aim to complete the hiring process in March or April, allowing for a smooth transition between the incoming Executive Director and myself.

Thank you for being part of this incredible community and supporting our work. I know that I will keep advocating, no matter what. I hope you will, too. Together, let's ensure T1International is powerful and sustainable to keep fighting for #insulin4all as long as it is needed into the future.

Related posts:

T1International and #insulin4all Advocates Score Major Win

T1International and #insulin4all Advocates Score Major Win

Following years of advocacy on affordable insulin for T1International, today Eli Lilly announced that vials of generic insulin Lispro will be available to all US customers for $25 effective May 1, 2023. Some other Eli Lilly insulins will also be made more affordable by the end of the year. Current list prices for insulin can be over $300 per vial. Read more

T1International Advocates Win: WHO Adds Long-Acting Insulin Analogues to EML

T1International Advocates Win: WHO Adds Long-Acting Insulin Analogues to EML

T1International’s global community of people living with and affected by diabetes and their allies celebrates a monumental advocacy win as the World Health Organization announced the addition of long-acting insulin analogues to the Model List of Essential medicines (EML). Read more